HOME >> BIOLOGY >> NEWS
NIH selects Pittsburgh institute as leader for HIV/AIDS prevention efforts

Pittsburgh, June 30 The University of Pittsburgh-affiliated Magee-Womens Research Institute is one of six institutions selected to lead HIV/AIDS prevention and treatment efforts by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Estimated at $285 million in funding for the first year, these leadership group awards represent the first step of a two-part restructuring process of the NIAID's clinical trials networks.

Sharon L. Hillier, Ph.D., professor of obstetrics, gynecology and reproductive sciences and of molecular genetics and biochemistry at the University of Pittsburgh School of Medicine, is principal investigator for the Pittsburgh consortium, which has been designated to lead the Microbicide Trials Network (MTN). The mission of the MTN is to develop new drugs and drug delivery systems to prevent HIV and its spread.

"The leading method of transmission for HIV/AIDS infection today is heterosexual intercourse," said Dr. Hillier, who also is a senior investigator at the Magee-Womens Research Institute. "And in many parts of the world, a woman's single biggest risk factor for the acquisition of HIV is being married. Currently, women have no way to protect themselves except condoms, and women do not control condom use."

Dr. Hillier's group is involved in evaluating drugs for the prevention of sexually transmitted infections such as HIV. Clinical trials have been designed to support the licensing of new agents for the prevention of HIV that could be used by women at risk of infection both in the U.S. and internationally. NIAID's decision to fund the MTN reflects a growing recognition that novel approaches to prevention will be needed to slow the epidemic of AIDS.

"Pittsburgh proved its scientific worth more than 50 years ago when the development of the Salk vaccine signaled an end to the scourge of polio," said Arthur S. Levine, M.D., senior vice
'"/>

Contact: Michele Baum
BaumMD@upmc.edu
412-647-3555
University of Pittsburgh Medical Center
30-Jun-2006


Page: 1 2 3

Related biology news :

1. Energy department selects 3 Bioenergy Research Centers for $375 million in federal funding
2. EPA selects Phylonix to screen compound library in zebrafish
3. OneWorld Health selects Odyssey Research for phase 4 study in India
4. NIH selects Childrens Hospital as Center of Excellence to train future generations of scientists
5. NIH selects Purdue to use phi29 DNA packaging motor for National Nanomedicine Development Center
6. IUBMB selects Wiley to publish Biochemistry and Molecular Biology Education
7. EMBO selects Europes best young independent scientists
8. NIH selects Burnham Institute for Exploratory Center for Human Embryonic Stem Cell Research
9. NHGRI selects 13 new targets for large-scale sequencing program
10. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
11. University of Pittsburgh School of Medicine researchers develop off-the-shelf vascular grafts

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While the ... economic downturn will only increase price pressures overall for the industry. The era of ... every product launch is critical. However, history shows that only a third of product ...
(Date:7/10/2020)... ... ... Today CJ BIO announced the first in a series of Food Ingredient ... that is revolutionizing ingredient mixes, nutritional content and flavor profiles across a range of ... 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of the IFT Annual Meeting ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio ... findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease ... hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... Modality ... for free its new white paper – Simulated Transport Methodologies. Regulatory expectations ... biologics licensing application (BLA). In response, Modality Solutions shares an explanation of ...
(Date:8/3/2020)... LEXINGTON, Ky. (PRWEB) , ... August 03, 2020 , ... ... innovative products for transformative growth, , Known as MediVet Biologics ... Health brand. , The new Ardent Animal Health will build on its ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... can combine up to three different materials for use with CRM, neurostimulation, vascular, ... to three materials to meet specific design requirements, performance, and cost criteria; especially ...
(Date:7/31/2020)... ... July 30, 2020 , ... Alucio™, ... announced the release of its signature product called Beacon - a content ... other field medical professionals. , Beacon helps MSLs streamline communication and ...
Breaking Biology Technology:
Cached News: